Le Lézard
Classified in: Health, Science and technology
Subject: HEALTH

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen


SAN ?WANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) -- Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.

As a bioequivalent version of Victoza® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA.

The successful development of Liraglutide highlights Adalvo's capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.

Adalvo's commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo's position as a trusted leader in the pharmaceutical industry.

Click Here To View Adalvo's Diabetes Portfolio

At Adalvo, there are no half-measures ? they are always on target. Their mission is to be faster and stronger than their competitors, driving their vision forward with a winning team.

Adalvo is committed to maintaining the highest standards of excellence in all their endeavors and looks forward to continuing to deliver innovative healthcare solutions that make a difference in the lives of patients worldwide.

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company's declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.

Adalvo takes pride in their ability to help partners reach their goals ? be those increasing revenues or pushing into new markets. Tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.

The company's purpose-driven culture is committed to improving the lives of patients around the world. Adalvo's dynamic leadership team brings significant experience and industry know-how, which has helped to establish the company as a reliable global partner in the industry.

Contacts: Gabrielle Cassar, [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1e895aa-f689-4215-a1f8-25285851af9d



These press releases may also interest you

at 03:09
Ricovr Healthcare is proud to announce that it has been awarded a competitive Small Business Innovation Research grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) for the development of its...

at 03:05
Saphetor SA, the creators of the global human genetics community VarSome, today announced European CE mark approval of the VarSome Clinical platform for the automated variant discovery, annotation, and interpretation of Next Generation Sequencing...

at 03:05
PK MED, a French biotech company, privately owned, and established in 2019 by Truffle Capital, announced it has secured a non-dilutive DeepTech financing of ? 1.5 million from Bpifrance. The funding will accelerate the company's project PKM-02, an...

at 03:00
Viewpoint, the acclaimed educational program hosted by Dennis Quaid, is excited to announce the development of a new episode in collaboration with Positive Approach to Care. This upcoming segment will focus on innovative approaches to cognitive...

at 03:00
CS Analytical Laboratory, the world's only cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to container testing for the pharmaceutical, biotechnology, and medical device...

at 03:00
New cognition/function and extensive plasma biomarker results of T3D-959 treatment from the Phase 2 PIONEER trial, in a modified intent-to treat population of mild to moderate Alzheimer's patients will be presented at the upcoming Alzheimer's...



News published on and distributed by: